Creative Planning’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Creative Planning’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-152	Closed	-$2K	–	4516
2017 Q2	$2K	Hold	152	–	–	﹤0.01%	4387
2017 Q1	$1K	Hold	152	–	–	﹤0.01%	4591
2016 Q4	$2K	Sell	152 -312	-67%	-$3.12K	﹤0.01%	4370
2016 Q3	$5K	Buy	464 +312	+205%	+$3.4K	﹤0.01%	3933
2016 Q2	$2K	Hold	152	–	–	﹤0.01%	4105
2016 Q1	$2K	Hold	152	–	–	﹤0.01%	4045
2015 Q4	$1K	Hold	152	–	–	﹤0.01%	4326
2015 Q3	$1K	Buy	+152	New	+$1.3K	﹤0.01%	4216
2015 Q2	–	Sell	-852	Closed	-$8K	–	3704
2015 Q1	$8K	Hold	852	–	–	﹤0.01%	3356
2014 Q4	$7K	Buy	852 +152	+22%	+$1.23K	﹤0.01%	3356
2014 Q3	$5K	Buy	+700	New	+$4.2K	﹤0.01%	3338
2013 Q3	–	Sell	-1,000	Closed	-$5K	–	3447
2013 Q2	$5K	Buy	+1,000	New	+$4.76K	﹤0.01%	2579

Other funds holding SCLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Creative Planning's SCLN Position: Q3 2017 in Review

Creative Planning sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 152 shares — an estimated $2K sold.

Creative Planning first reported a position in SCLN in Q2 2013 and held it in 12 quarters. The position peaked at $8K in Q1 2015. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

Creative Planning reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
Creative Planning sold 152 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $2K.
Creative Planning first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 12 quarters.
Creative Planning's Sciclone Pharmaceuticals Inc position peaked at $8K in Q1 2015.
129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Creative Planning's 13F filing for Q3 2017, filed 17 Oct 2017.